BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Long (1Y)
Credit Suisse maintains outperform on Aurobindo Pharma
New launches have picked up with approvals.
Expect faster approvals to continue. See a 20 per cent CAGR in US sales over
next two years. Margins to expand in future.